These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35101893)

  • 21. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.
    Collier DA; Ferreira IATM; Kotagiri P; Datir RP; Lim EY; Touizer E; Meng B; Abdullahi A; ; Elmer A; Kingston N; Graves B; Le Gresley E; Caputo D; Bergamaschi L; Smith KGC; Bradley JR; Ceron-Gutierrez L; Cortes-Acevedo P; Barcenas-Morales G; Linterman MA; McCoy LE; Davis C; Thomson E; Lyons PA; McKinney E; Doffinger R; Wills M; Gupta RK
    Nature; 2021 Aug; 596(7872):417-422. PubMed ID: 34192737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect.
    Cin D; Soguksu P; Oren MM; Ozgulnar N; Agacfidan A; Mese S
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
    Griffante G; Chandel S; Ferrante D; Caneparo V; Capello D; Bettio V; Borgogna C; Aleni C; Esposito S; Sarro A; Vasile A; Comba M; Testa T; Cotrupi G; De Andrea M; Bortoluzzi S; Gariglio M
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination.
    Hyun H; Nham E; Seong H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
    Front Immunol; 2024; 15():1385135. PubMed ID: 38756783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
    Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
    Front Immunol; 2022; 13():830710. PubMed ID: 35173741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals.
    Becker M; Dulovic A; Junker D; Ruetalo N; Kaiser PD; Pinilla YT; Heinzel C; Haering J; Traenkle B; Wagner TR; Layer M; Mehrlaender M; Mirakaj V; Held J; Planatscher H; Schenke-Layland K; Krause G; Strengert M; Bakchoul T; Althaus K; Fendel R; Kreidenweiss A; Koeppen M; Rothbauer U; Schindler M; Schneiderhan-Marra N
    Nat Commun; 2021 May; 12(1):3109. PubMed ID: 34035301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
    Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
    Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serological response to a single dose of a SARS-CoV-2 mRNA vaccine.
    Ramos A; Cardoso MJ; Norton P; Sarmento A; Guimarães JT
    J Virol Methods; 2021 Oct; 296():114223. PubMed ID: 34224753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
    Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
    mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
    Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
    EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination.
    Young BE; Seppo AE; Diaz N; Rosen-Carole C; Nowak-Wegrzyn A; Cruz Vasquez JM; Ferri-Huerta R; Nguyen-Contant P; Fitzgerald T; Sangster MY; Topham DJ; Järvinen KM
    JAMA Pediatr; 2022 Feb; 176(2):159-168. PubMed ID: 34757387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
    Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
    mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.
    Sulbaran G; Maisonnasse P; Amen A; Effantin G; Guilligay D; Dereuddre-Bosquet N; Burger JA; Poniman M; Grobben M; Buisson M; Dergan Dylon S; Naninck T; Lemaître J; Gros W; Gallouët AS; Marlin R; Bouillier C; Contreras V; Relouzat F; Fenel D; Thepaut M; Bally I; Thielens N; Fieschi F; Schoehn G; van der Werf S; van Gils MJ; Sanders RW; Poignard P; Le Grand R; Weissenhorn W
    Cell Rep Med; 2022 Feb; 3(2):100528. PubMed ID: 35233549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
    Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
    J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.